BioCentury
ARTICLE | Clinical News

Staphylococcus lysin regulatory update

August 24, 2015 7:00 AM UTC

FDA granted Fast Track designation to ContraFect’s CF-301 to treat Staphylococcus aureus bloodstream infections, including methicillin-resistant S. aureus (MRSA). The company expects to complete a Pha...